Evidence map›Paper›PMID 35070301›Full record

ArticleMolecular and clinical oncology2022

Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers.

Gabriel Allo, Ahu Damla Can, Roger Wahba, Nils Vogel, Tobias Goeser, Fabian Kütting, Dirk Waldschmidt

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gabriel AlloDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Ahu Damla CanDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Roger WahbaDepartment of General, Visceral and Cancer and Transplant Surgery, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Nils VogelDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Tobias GoeserDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Fabian KüttingDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
Dirk WaldschmidtDepartment for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany.
University Hospital Cologne · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary tract cancers (BTC) are rare but aggressive. Due to limited anti-tumor effects of current second- and later-line treatment regimens, novel treatment options are required. Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil (FOLFnal-IRI) achieved promising results as a second-line treatment in patients with pancreatic cancer, warranting further investigation in BTC. In the present study, a retrospective analysis of patients receiving FOLFnal-IRI after initial platinum-based chemotherapy for advanced BTC between January 2016 and August 2020 at the University Hospital Cologne (Cologne, Germany) was performed. A total of 11 patients were identified who met the inclusion criteria. A total of 4 patients (36.4%) were female and the median age was 54 years. The proportion of patients suffering from gallbladder carcinoma, intrahepatic and extrahepatic cholangiocarcinoma was 18.2, 63.6 and 9.1%, respectively. Furthermore, 7 patients (63.6%) received FOLFnal-IRI as their second-, 3 (27.3%) as third- and one (9.1%) as their fourth-line therapy. The disease control rate was 54.5% and 3 grade III toxicities were recorded. Progression-free survival and overall survival (OS) after initiation of FOLFnal-IRI was 5.1 and 12.4 months, respectively. OS after initial diagnosis was 24.7 months. FOLFnal-IRI demonstrated promising antitumor potential with an acceptable safety profile as a subsequent therapy regimen in advanced biliary tract malignancies. Further randomized controlled trials of its value as a treatment option for BTC appear justified.

Indexed as

biliary tract cancerliposomal irinotecanoverall survivalprogression free survivalsecond-line chemotherapy

Identifiers

PMID35070301
PMCPMC8764657
OpenAlexW4200604905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.